Sanofi And GSK Face DOJ Probes Over Zantac Cancer Risk
By Hailey Konnath (July 30, 2020, 10:46 PM EDT) -- Both Sanofi-Aventis US LLC and GlaxoSmithKline LLC are facing U.S. Department of Justice investigations over Zantac and allegations the heartburn drug causes cancer, the companies have said in a pair of U.S. Securities and Exchange Commission filings.
Sanofi said in its Form 6-K on Wednesday that it was notified of the probe on June 6. Specifically, the DOJ's Civil Division and the U.S. Attorney's Office for the Eastern District of Pennsylvania are looking into claims the pharmaceutical manufacturer violated the False Claims Act by failing to disclose information on the potential presence of N-nitrosodimethylamine, or NDMA, which has been linked to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!